benserazide has been researched along with MPTP Neurotoxicity Syndrome in 4 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Maximal dyskinesias scores of the MPTP monkeys correlated significantly with [(3)H]Ro25-6981 specific binding in the rostral and caudal striatum." | 1.35 | Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias. ( Belkhir, S; Di Paolo, T; Dridi, M; Grégoire, L; Meltzer, LT; Morissette, M; Ouattara, B; Samadi, P, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iggena, D | 1 |
| Klein, C | 1 |
| Rasińska, J | 1 |
| Sparenberg, M | 1 |
| Winter, Y | 1 |
| Steiner, B | 1 |
| Belaid, H | 1 |
| Adrien, J | 1 |
| Laffrat, E | 1 |
| Tandé, D | 1 |
| Karachi, C | 1 |
| Grabli, D | 1 |
| Arnulf, I | 1 |
| Clark, SD | 1 |
| Drouot, X | 1 |
| Hirsch, EC | 1 |
| François, C | 1 |
| Ouattara, B | 1 |
| Belkhir, S | 1 |
| Morissette, M | 1 |
| Dridi, M | 1 |
| Samadi, P | 1 |
| Grégoire, L | 1 |
| Meltzer, LT | 1 |
| Di Paolo, T | 1 |
| Berton, O | 1 |
| Guigoni, C | 1 |
| Li, Q | 1 |
| Bioulac, BH | 1 |
| Aubert, I | 1 |
| Gross, CE | 1 |
| Dileone, RJ | 1 |
| Nestler, EJ | 1 |
| Bezard, E | 1 |
4 other studies available for benserazide and MPTP Neurotoxicity Syndrome
| Article | Year |
|---|---|
Physical activity sustains memory retrieval in dopamine-depleted mice previously treated with L-Dopa.
Topics: Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine; Drug | 2019 |
Sleep disorders in Parkinsonian macaques: effects of L-dopa treatment and pedunculopontine nucleus lesion.
Topics: Animals; Benserazide; Cholinergic Neurons; Diphtheria Toxin; Drug Combinations; Levodopa; Macaca fas | 2014 |
Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias.
Topics: Animals; Autoradiography; Behavior, Animal; Benserazide; Benzoxazoles; Cabergoline; Corpus Striatum; | 2009 |
Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Disease Models, A | 2009 |